DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ: 067080)
South Korea
· Delayed Price · Currency is KRW 19,500
+890 (4.78%)
Oct 11, 2024, 9:00 AM KST
DAE HWA Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | 2014 - 2010 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | 2014 - 2010 |
| Operating Revenue | 115,306 | 114,610 | 110,143 | 122,200 | 142,288 | 139,080 | Upgrade
|
| Other Revenue | 0 | -0 | - | - | - | - | Upgrade
|
| Revenue | 115,306 | 114,610 | 110,143 | 122,200 | 142,288 | 139,080 | Upgrade
|
| Revenue Growth (YoY) | 8.65% | 4.06% | -9.87% | -14.12% | 2.31% | 3.08% | Upgrade
|
| Cost of Revenue | 66,944 | 66,511 | 65,044 | 76,044 | 97,911 | 97,072 | Upgrade
|
| Gross Profit | 48,363 | 48,099 | 45,099 | 46,156 | 44,377 | 42,008 | Upgrade
|
| Selling, General & Admin | 34,166 | 33,233 | 33,771 | 30,715 | 31,462 | 30,791 | Upgrade
|
| Research & Development | 3,972 | 4,198 | 4,687 | 6,183 | 5,202 | 3,806 | Upgrade
|
| Other Operating Expenses | 311.01 | 342.4 | 508.53 | 356.04 | 315.49 | 185.57 | Upgrade
|
| Operating Expenses | 42,427 | 42,376 | 39,968 | 38,039 | 38,973 | 36,418 | Upgrade
|
| Operating Income | 5,936 | 5,723 | 5,131 | 8,116 | 5,404 | 5,591 | Upgrade
|
| Interest Expense | -4,943 | -3,963 | -1,457 | -1,323 | -1,171 | -1,132 | Upgrade
|
| Interest & Investment Income | 322.93 | 331.51 | 283.84 | 282.34 | 257.93 | 310.09 | Upgrade
|
| Earnings From Equity Investments | 209.89 | 209.89 | - | 7,847 | 284.76 | 593.53 | Upgrade
|
| Currency Exchange Gain (Loss) | 66.64 | 76.63 | 171.61 | -338.69 | 14.93 | 77.56 | Upgrade
|
| Other Non Operating Income (Expenses) | 5,260 | 3,886 | 2,881 | 2,043 | 1,290 | 981.2 | Upgrade
|
| EBT Excluding Unusual Items | 6,853 | 6,264 | 7,011 | 16,628 | 6,081 | 6,421 | Upgrade
|
| Impairment of Goodwill | -921.78 | -921.78 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 9,011 | 9,122 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -274.39 | -144.62 | 3,305 | -111.05 | -9.36 | 35.95 | Upgrade
|
| Pretax Income | 14,667 | 14,319 | 10,315 | 16,517 | 6,071 | 6,456 | Upgrade
|
| Income Tax Expense | 5,362 | 5,247 | 3,962 | 4,403 | 2,316 | 2,345 | Upgrade
|
| Earnings From Continuing Operations | 9,305 | 9,072 | 6,353 | 12,113 | 3,755 | 4,111 | Upgrade
|
| Minority Interest in Earnings | 1,457 | 1,469 | 295.39 | 541.32 | -25.66 | -200.16 | Upgrade
|
| Net Income | 10,762 | 10,541 | 6,648 | 12,654 | 3,729 | 3,911 | Upgrade
|
| Net Income to Common | 10,762 | 10,541 | 6,648 | 12,654 | 3,729 | 3,911 | Upgrade
|
| Net Income Growth | 126.18% | 58.55% | -47.46% | 239.31% | -4.64% | - | Upgrade
|
| Shares Outstanding (Basic) | 17 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | 3.43% | 3.42% | 0.06% | -0.01% | -0.12% | 4.07% | Upgrade
|
| EPS (Basic) | 617.61 | 600.00 | 375.95 | 716.00 | 211.00 | 221.00 | Upgrade
|
| EPS (Diluted) | 617.61 | 600.00 | 375.95 | 716.00 | 211.00 | 221.00 | Upgrade
|
| EPS Growth | 127.72% | 59.60% | -47.49% | 239.34% | -4.52% | - | Upgrade
|
| Free Cash Flow | -13,553 | -12,536 | 5,676 | 3,683 | 4,758 | -1,351 | Upgrade
|
| Free Cash Flow Per Share | -746.91 | -685.45 | 320.98 | 208.39 | 269.18 | -76.32 | Upgrade
|
| Dividend Per Share | 150.000 | 150.000 | 150.000 | - | - | - | Upgrade
|
| Gross Margin | 41.94% | 41.97% | 40.95% | 37.77% | 31.19% | 30.20% | Upgrade
|
| Operating Margin | 5.15% | 4.99% | 4.66% | 6.64% | 3.80% | 4.02% | Upgrade
|
| Profit Margin | 9.33% | 9.20% | 6.04% | 10.36% | 2.62% | 2.81% | Upgrade
|
| Free Cash Flow Margin | -11.75% | -10.94% | 5.15% | 3.01% | 3.34% | -0.97% | Upgrade
|
| EBITDA | 11,733 | 11,385 | 9,609 | 12,308 | 9,281 | 9,159 | Upgrade
|
| EBITDA Margin | 10.18% | 9.93% | 8.72% | 10.07% | 6.52% | 6.59% | Upgrade
|
| D&A For EBITDA | 5,798 | 5,663 | 4,478 | 4,191 | 3,877 | 3,569 | Upgrade
|
| EBIT | 5,936 | 5,723 | 5,131 | 8,116 | 5,404 | 5,591 | Upgrade
|
| EBIT Margin | 5.15% | 4.99% | 4.66% | 6.64% | 3.80% | 4.02% | Upgrade
|
| Effective Tax Rate | 36.56% | 36.65% | 38.41% | 26.66% | 38.15% | 36.32% | Upgrade
|
| Advertising Expenses | - | 3,997 | 5,075 | 4,803 | 5,644 | 5,268 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.